News
Sarepta sells $174M in Arrowhead shares to fund a $100M milestone payment as part of its RNAi drug collaboration.
Asianet Newsable on MSN1h
This Analyst Says Sarepta Lost Credibility By Exiting Arrowhead At A Loss, But Retail Sees Stock Hitting $30 By Next Week
H.C. Wainwright has a ‘Sell’ rating on the stock and a $5 price target, representing a near 75% downside from the stock’s ...
Investor's Business Daily on MSN28m
Eli Lilly Hikes UK Mounjaro Price By Up To 170% As Trump Pressure Mounts
Eli Lilly said Thursday it will hike the UK list price of its diabetes and weight-loss drug Mounjaro by up to 170%.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback